We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
FUJIREBIO

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
18 Mar 2021 - 21 Mar 2021
13 Apr 2021 - 16 Apr 2021

Biosensing Microneedle Patch Quantifies Biomarkers in Interstitial Fluid

By LabMedica International staff writers
Posted on 10 Feb 2021
Print article
Image: A microneedle patch has been developed that can be applied to the skin, capture a biomarker of interest from interstitial fluid and, due to its unprecedented sensitivity, allow clinicians to detect its presence (Photo courtesy of Sisi Cao).
Image: A microneedle patch has been developed that can be applied to the skin, capture a biomarker of interest from interstitial fluid and, due to its unprecedented sensitivity, allow clinicians to detect its presence (Photo courtesy of Sisi Cao).
Interstitial fluid (ISF) compared with other peripheral biofluids such as saliva, sweat and tears is a particularly rich source of soluble bioanalytes including proteins, peptides, metabolites and nucleic acids that exhibit close correlation with blood.

ISF is a rich source of biomolecules, densely packed with everything from neurotransmitters to cellular waste. However, to analyze biomarkers in ISF, conventional method generally requires extraction of ISF from skin. This method is difficult and usually the amount of ISF that can be obtained is not sufficient for analysis. That has been a major hurdle for developing microneedle-based biosensing technology.

Bioengineers and medical scientists at the Washington University in St Louis (St Louis, MO, USA) have developed a biosensing microneedle patch that can be applied to the skin, capture a biomarker of interest and, due to its unprecedented sensitivity, allow clinicians to detect its presence. In addition to the low cost and ease of use, these microneedle patches have another advantage over blood draws, perhaps the most important feature for some: they are entirely pain-free.

Finding a biomarker using these microneedle patches is similar to blood testing. But instead of using a solution to find and quantify the biomarker in blood, the microneedles directly capture it from the liquid that surrounds the cells in skin, which is called dermal interstitial fluid (ISF). Once the biomarkers have been captured, they are detected in the same way, using fluorescence to indicate their presence and quantity. The patches are almost pain-free. They go about 400 microns deep into the dermal tissue and they do not even touch sensory nerves.

The team used "plasmonic-fluors," an ultrabright fluorescence nanolabel. Compared with traditional fluorescent labels, when an assay was done on microneedle patch using plasmonic-fluor, the signal of target protein biomarkers shined about 1,400 times as bright and become detectable even when they are present at low concentrations. For people with chronic conditions that require regular monitoring, microneedle patches could eliminate unnecessary trips to the hospital, saving money, time and discomfort.

The authors noted that various protein biomarker levels in the ISF are not well characterized and understood, which is an important bottleneck in the clinical translation of this technology. However the technology demonstrated serves as an efficient tool for biomedical and clinical scientists to fill this knowledge gap and propel the technology towards clinical applications. The study was published on January 22, 2021 in the journal Nature Biomedical Engineering.

Related Links:
Washington University in St Louis

New
Gold Supplier
Clinical Chemistry Series
Clinical Chemistry Series
New
Hematology Analyzer
DxH 560 AL
New
Gold Supplier
Nucleic Acid Extractor (Magnetic Bead Method)
Singu20
New
Silver Supplier
Nucleic Acid Extractor
Pre-NAT II

Print article

Channels

Molecular Diagnostics

view channel
Image: Histopathologic image from a patient with Li Fraumeni syndrome showing accumulation of mutant TP53 in tumoral cells (Photo courtesy of Thierry Soussi, PhD).

Clinical Germline Testing Evaluated for Pediatric Cancer Patients

Pediatric cancer is rare, with fewer than 10,000 solid tumors diagnosed in children annually in the USA. Previous studies interrogating germline predisposition broadly across pediatric cancer types have... Read more

Industry

view channel
Illustration

Mindray and Tencent AI Lab to Jointly Develop AI Products for Blood Disease Screening and In Vitro Diagnosis

Shenzhen Mindray Biomedical Electronics Co., Ltd. (Shenzhen, China) has signed an AI cooperation framework agreement with Tencent AI Lab (Shenzhen, China) to jointly develop AI products for blood cell... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.